Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocodone bitartrate + aspirin is a combination prescription analgesic product containing hydrocodone (an opioid pain reliever) and aspirin (a nonsteroidal anti-inflammatory drug). Hydrocodone acts as a full opioid agonist at the μ-opioid receptor in the brain and spinal cord, providing analgesia by altering pain perception and response, while aspirin inhibits prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects[5]. This product is intended for oral administration only and is reserved for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate[5]. The combination is classified as a Schedule II controlled substance due to the high risk of dependency, abuse, and misuse associated with opioid content[5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocodone bitartrate + aspirin.